| Metric | Value ($ M) | Q1 FY25 |
|---|---|---|
| Revenue | 6.47 | 56.1% |
| Total Income | 6.47 | 56.1% |
| Expenditure | 134.98 | 34.5% |
| PBT | -122.11 | 39.7% |
| Net Profit | -117.50 | 42.0% |
| OPM | — | |
| NPM | — | |
| EPS | -0.22 | 56.0% |
Recursion Reports Q1 2026 Financial Results and Provides Business Update
06 May 2026 · 6 May, 4:07 pm
Summary
Recursion Pharmaceuticals reported its first quarter 2026 financial results and business updates. The company highlighted strong pipeline execution, clinical progress, and platform advancement. Total revenue for the quarter was $6.5 million, compared to $14.7 million in the first quarter of 2025. The net loss for the quarter was $117.5 million, a decrease from the $202.5 million net loss in the same period last year. The company's cash runway is expected to extend into early 2028 without additional financing, with an operational cash burn of less than $390 million for 2026.
Key Highlights
- 1
Recursion reported business updates highlighting strong continued pipeline execution, clinical progress and platform advancement for the first quarter ended March 31, 2026.
- 2
Early clinical data in solid tumors demonstrate a well-tolerated safety profile and predictable, dose-dependent pharmacokinetics for REC-1245 (RBM39 degrader).
- 3
REC-4881 (FAP / MEK1/2) showed strong Phase 2 efficacy signals with FDA engagement initiated to define potential registrational pathway; update expected in 2H26.
- 4
The first patient was dosed in Phase 1 for REC-4539 (LSD1 inhibitor).
- 5
Recursion reiterates 2026 guidance of <$390 million operational cash burn, supporting runway into early 2028 without additional financing.
- 6
Total revenue was $6.5 million for the first quarter of 2026, compared to $14.7 million for the first quarter of 2025.
- 7
Net loss was $117.5 million for the first quarter of 2026, compared to a net loss of $202.5 million for the first quarter of 2025.
Management Comments
Najat Khan
Ph.D.
“We are seeing strong momentum and execution across our portfolio, with increasing evidence that our full stack platform can translate biological and chemical insights into differentiated clinical programs. Recent progress, including encouraging initial safety and PK data in REC-1245 and the first patient dosed in REC-4539, represents a growing set of proof points that demonstrate our ability to translate platform insights into clinical programs. This momentum reflects the strength of our end-to-end AI platform, with multiple differentiated internal and partnered programs advancing into and through the clinic."
Vicki Goodman
M.D.
“I look forward to working with Najat, the leadership team, and the broader organization to advance the pipeline, support smart and disciplined development decisions, and help bring impactful new therapies to patients.”
Informational and educational content only. Not investment advice.